Hyperlipidemia Saudi Diploma in Family Medicine Center of

Hyperlipidemia Saudi Diploma in Family Medicine Center of Post Graduate Studies in Family Medicine Presented by: Dr. Zekeriya Aktürk zekeriya. akturk@gmail. com www. aile. net 1 / 29

Top 10 cause of Death in K. S. A.

Top 10 cause of Death in K. S. A. 30 %

• Cardiovascular diseases (CVD) are the main cause of morbidity and mortality among the Saudi population 1 • A significant proportion of hospital admissions is due to CVD, whether acute or chronic or to cardiac procedures including angiograms 2 1 -Al Balla SR, . J Trop Med Hyg 1993; 96: 157 -62 -Bamgboye EA, Saudi Med J 1993; 13(1): 8 -13. ]. 2

Prevalence of dyslipidemia in Saudi Adults • The overall prevalence of hypercholesterolemia TC > 200 mg/ d. L: 35. 4%. • The overall prevalence of hypertriglyceridemia TG > 150 mg/ d. L) : 49. 6%. • HDL Values in men and women Men <40 mg/d. L: 74. 8 % Women <50 mg/d. L: 81. 8 Al-Nozha MM. et al. Metabolic syndrome in Saudi Arabia. Saudi Med J 2005; 26 (12): 1918 -1925

Hyperlipidemia Michele Ritter, M. D. Argy Resident – February, 2007 6 / 29

The story of lipids • Chylomicrons transport fats from the intestinal mucosa to the liver • In the liver, the chylomicrons release triglycerides and some cholesterol and become low-density lipoproteins (LDL). • LDL then carries fat and cholesterol to the body’s cells. • High-density lipoproteins (HDL) carry fat and cholesterol back to the liver for excretion. 7 / 29

The story of lipids (cont. ) • When oxidized LDL cholesterol gets high, atheroma formation in the walls of arteries occurs, which causes atherosclerosis. • HDL cholesterol is able to go and remove cholesterol from the atheroma. • Atherogenic cholesterol → LDL, VLDL, IDL 8 / 29

Atherosclerosis 9 / 29

Causes of Hyperlipidemia • • • Diet Hypothyroidism Nephrotic syndrome Anorexia nervosa Obstructive liver disease • Obesity • Diabetes mellitus • Pregnancy • Obstructive liver disease • Acute heaptitis • Systemic lupus erythematousus • AIDS (protease inhibitors) 10 / 29

Dietary sources of Cholesterol Type of Fat Main Source Effect on Cholesterol levels Monounsaturated Olives, olive oil, canola oil, peanut oil, cashews, almonds, peanuts and most other nuts; avocados Lowers LDL, Raises HDL Polyunsaturated Corn, soybean, safflower and cottonseed oil; fish Lowers LDL, Raises HDL Saturated Whole milk, butter, cheese, and ice cream; red meat; chocolate; coconuts, coconut milk, coconut oil , egg yolks, chicken skin Raises both LDL and HDL Trans Most margarines; vegetable shortening; Raises LDL partially hydrogenated vegetable oil; deep-fried chips; many fast foods; most commercial baked goods 11 / 29

Hereditary Causes of Hyperlipidemia • Familial Hypercholesterolemia • Codominant genetic disorder, coccurs in heterozygous form • Occurs in 1 in 500 individuals • Mutation in LDL receptor, resulting in elevated levels of LDL at birth and throughout life • High risk for atherosclerosis, tendon xanthomas (75% of patients), tuberous xanthomas and xanthelasmas of eyes. • Familial Combined Hyperlipidemia • Autosomal dominant • Increased secretions of VLDLs • Dysbetalipoproteinemia • Affects 1 in 10, 000 • Results in apo E 2, a binding-defective form of apo. E (which usually plays important role in catabolism of chylomicron and VLDL) • Increased risk for atherosclerosis, peripheral vascular disease • Tuberous xanthomas, striae palmaris 12 / 29

Checking lipids • Nonfasting lipid panel • measures HDL and total cholesterol • Fasting lipid panel • Measures HDL, total cholesterol and triglycerides • LDL cholesterol is calculated: – LDL cholesterol = total cholesterol – (HDL + triglycerides/5) 13 / 29

When to check lipid panel • Two different Recommendations – Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) – Beginning at age 20: obtain a fasting (9 to 12 hour) serum lipid profile consisting of total cholesterol, LDL, HDL and triglycerides – Repeat testing every 5 years for acceptable values – United States Preventative Services Task Force – Women aged 45 years and older, and men ages 35 years and older undergo screening with a total and HDL cholesterol every 5 years. – If total cholesterol > 200 or HDL <40, then a fasting panel should be obtained – Cholesterol screening should begin at 20 years in patients with a history of multiple cardiovascular risk factors, diabetes, or family history of either elevated cholesteral levels or premature cardiovascular disease. 14 / 29

Goals for Lipids • LDL – < 100 →Optimal – 100 -129 → Near optimal – 130 -159 → Borderline – 160 -189→ High – ≥ 190 → Very High • Total Cholesterol – < 200 → Desirable – 200 -239 → Borderline – ≥ 240 → High • HDL – < 40 → Low – ≥ 60 → High • Serum Triglycerides – – < 150 → normal 150 -199 → Borderline 200 -499 → High ≥ 500 → Very High 15 / 29

Determining Cholesterol Goal (LDL!) • Look at JNC 7 Risk Factors • Cigarette smoking • Hypertension (BP ≥ 140/90 or on antihypertensives) • Low HDL cholesterol (< 40 mg/d. L) • Family History of premature coronary heart disease (CHD) (CHD in first-degree male relative <55 or CHD in first-degree female relative < 65) • Age (men ≥ 45, women ≥ 55) 16 / 29

Determining Goal LDL • CHD and CHD Risk Equivalents: – Peripheral Vascular Disease – Cerebral Vascular Accident – Diabetes Mellitus 17 / 29

LDL Goals • 0 -1 Risk Factors: • LDL goal is 160 • If LDL ≥ 160: Initiate TLC (therapeutic lifestyle changes) • If LDL ≥ 190: Initiate pharmaceutical treatment • 2 + Risk Factors • LDL goal is 130 • If LDL ≥ 130: Initiate TLC • If LDL ≥ 160: Initiate pharmaceutical treatment • CHD or CHD Risk Equivalent • LDL goal is 100 (or 70) • If LDL ≥ 100: Initiate TLC and pharmaceutical treatment 18 / 29

Treatment of Hyperlipidemia • Lifestyle modification – Low-cholesterol diet – Exercise 19 / 29

Medications for Hyperlipidemia Drug Class Agents Effects (% change) Side Effects HMG Co. A reductase inhibitors Lovastatin Pravastatin LDL (18 -55), HDL (5 -15) Triglycerides (7 -30) Myopathy, increased liver enzymes Cholesterol absorption inhibitor Ezetimibe LDL( 14 -18), HDL (1 -3) Triglyceride (2) Headache, GI distress LDL (15 -30), HDL (15 -35) Triglyceride (20 -50) Nicotinic Acid Fibric Acids Gemfibrozil Fenofibrate Bile Acid sequestrants Cholestyramine LDL (5 -20), HDL (10 -20) Triglyceride (20 -50) LDL HDL No change in triglycerides Flushing, Hyperglycemia, Hyperuricemia, GI distress, hepatotoxicity Dyspepsia, gallstones, myopathy GI distress, constipation, decreased absorption of other drugs 20 / 29

21 / 29

Case # 1 • A 55 -year-old woman without symptoms of CAD seeks assessment and advice for routine health maintenance. Her blood pressure is 135/85 mm Hg. She does not smoke or have diabetes and has been postmenopausal for 3 years. Her BMI is 24. Lipoprotein analysis shows a total cholesterol level of 240 mg/d. L, an HDL level of 55 mg/d. L, a triglyceride level of 85 mg/d. L and a LDL level is 180 mg/d. L. The patient has no family history of premature CAD. 22 / 29

Case # 1 (cont. ) • What is the goal LDL in this woman? • What would you do if exercise/diet change do not improve cholesterol after 3 months? • How would your management change if she complained of claudication with walking? 23 / 29

Case # 2 • A 40 - year-old man without significant past medical history comes in for a routine annual exam. He has no complaints but is worried because his father had a “heart attack” at the age of 45. He is a current smoker and has a 23 -pack year history of tobacco use. A fasting lipid panel reveals a LDL 170 mg/d. L and an HDL of 35 mg/d. L. Serum Triglycerides were 140 mg/d. L. Serum chemistries including liver panel are all normal. 24 / 29

Case # 2 (cont. ) • What is this patient’s goal LDL? • Would you start medication, and if so, what? 25 / 29

Case # 3 • A 65 year-old woman with medical history of Type II diabetes, obesity, and hypertension comes to your office for the first time. She has been told her cholesterol was elevated in the past and states that she has been following a “low cholesterol diet” for the past 6 months after seeing a dietician. She had a normal exercise stress test last year prior to knee replacement surgery and has never had symptoms of CHD. A fasting lipid profile was performed and revealed a LDL 130, HDL 30 and a total triglyceride of 300. Her Hgba 1 c is 6. 5%. 26 / 29

Case # 3 (cont. ) • What is this patient’s goal LDL? • What medication would you consider starting in this patient? • What labs would you want to monitor in this patient? 27 / 29

HYPERLIPIDEMIA Brian V. Reamy, MD, Colonel, USAF, MC Chair – Department of Family Medicine Uniformed Services University 28 / 29

Why Bother? • Optimum treatment of lipids helps in the primary & secondary prevention of ASCVD; still our nation’s #1 killer 29 / 29

Why Bother? • ASCVD has been #1 cause of death every year since 1900 with exception of 1918. • 50% of CVD diagnoses and 15% of CVD deaths are in patients < 65 years of age • Many young adults have 2 or more risk factors that go unrecognized and untreated. • HUGE opportunity to prevent disease!! 30 / 29

NCEP/ATP III – 15 May 2001 • • • www. nhlbi. nih. gov LDL goals lowered Raised acceptable HDL to 40 Lowered TG goal to 150 Risk Factor assessment enhanced with the 10 -yr Framingham risk calculator • Added the Metabolic Syndrome to Tx 31 / 29

NCEP/ATP III – 9 Steps • Step 1: Obtain, complete & fasting lipids. • Interpret: LDL < 100 mg/dl optimal LDL 100 -129 near optimal LDL 130 -159 borderline high LDL 160 -189 high LDL >190 very high (mg/dl x 0. 0259 mmol/l = SI units) 32 / 29

NCEP/ATP III • Step 2: Identify if patient has CAD or equivalent (PAD, DM, AAA, Carotid) • Step 3: Risk factor assessment (HTN, FHx, Tob, Age & Sex, HDL<40 or >60) • Step 4: If 2 or more risk factors; do Framingham 10 -yr risk assessment. 33 / 29

Framingham Ten Year Risk Men Women 34 / 29

Framingham Ten Year Risk 0 35 / 29

Framingham Ten Year Risk 0 3 Non-Smoker 0 36 / 29

Framingham Ten Year Risk 0 3 0 1 HDL = 43 37 / 29

Framingham Ten Year Risk 0 3 0 1 0 SBP = 119, untreated 4 38 / 29

Framingham Ten Year Risk 0 3 0 1 0 4 39 / 29

NCEP/ATP III – Step 5 Risk Category LDL Goal CHD/10 yr <100 mg/dl risk>20% (high) 2+RF or <130 mg/dl 10 yr<20% (Medium) 0 -1 risk <160 mg/dl factors (low) Start T. L. C. Start Drug Treatment >100 mg/dl >100 – 129 mg/dl >130 – 160 mg/dl >160 – 40 / 29 190 mg/dl

NCEP/ATP III – Step 6 • Initiate Therapeutic Lifestyle Changes (TLC) – AHA Step 2 diet – Soluble fiber 10 -25 gm/day – Plant sterols/Sitostanol (Benecol®, Take Control® margarines) - lower LDL 10% – Increased exercise – Weight management 41 / 29

NCEP/ATP III – Step 7 • Add drug therapy simultaneously to TLC in patients with CHD or equivalent. Add drugs after 3 months if TLC not effective in other risk categories. • Best unbiased source for review of drug treatment: “The Medical Letter: Choice of lipid regulating drugs” 43: 2001, pp 43 -48 and 2003; 1; 77 -79. 42 / 29

Drugs – Step 7 (cont. ) • Resins- (cholestyramine, colestid, colesevelam): lower LDL; adjunct to statins; GI side effects/malabsorption issues • Niacin- “miracle agent”, cheap & moves every parameter in the right direction. But, side effects problematic. NIASPAN® easier to tolerate. Need slow dose titration and pre-med with ASA. Caution with Diabetes; can worsen glycemic control if HBA 1 C >7. 5 at baseline. Most potent agent at increasing HDL. 43 / 29

Drugs – Step 7 (cont) • Fibrates – (fenofibrate, gemfibrozil) lower TG and raise HDL. Can combine with statins but caution re: hepatic side effects. Cutting statin dose by ½ is good rule. *Fenofibrate qd & less side effects, >$$ • If combining w/ a statin use fenofibrate; gemfibrozil has > rates of rhabdomyolysis 44 / 29

Newer Drugs – Step 7 (cont. ) • Ezetimibe (Zetia®)- new class that inhibits the intestinal absorption of cholesterol. Lowers LDL 17%, TG 6%, increases HDL by 1. 3%. Combined with a statin increases effects of statin by 10 -15% w/o side effects. VERY well tolerated at 10 mg/d. 45 / 29

Newer Drugs – Step 7 (cont) • Lovastatin + Niacin (Advicor®)- in fixed combos 20/500, 20/750, 20/1000. Increase dose monthly up to max 40/2000. Max dose w/ LDL decrease 45%, TG 42%, and HDL increase by 41%. Causes less flushing and hepatic effects than any niacin formulation. Greater risk of myopathy than a statin alone. 46 / 29

Newer Drugs – Step 7 • Simvastatin(10/20/40/80) + Ezetimibe 10 mg: VYTORIN® • OMACOR: concentrated omega-3’s; 4 capsules = 12 OTC fish oil capsules • Can interfere with clotting times; caution in folks on warfarin 47 / 29

Drugs – Step 7 (cont. ) • Statins- All w/ anti-inflammatory effects. None safe in pregnancy. All are more potent by 10 -15% with evening dosing. - muscle pain = 1 -5% - hepatitis (transaminases>3 x nl. ) = 0. 5% - rhabdomyolysis = rare; incidence rates per million Rx’s: pravastatin 0. 04, lovastatin 0. 19 atorvastatin 0. 04, simvastatin 0. 12. (cerivistatin was 16 -80 x these rates!!) 48 / 29

Drugs – Step 7 (cont. ) • Atorvastatin – great LDL & TG lowering • Lovastatin: take w/ food; generic version • Pravastatin: least drug interactions due to different elimination pathway; take on empty stomach • Simvastatin: lots of prevention data, potent • Fluvastatin: less potent; poor prevention data • Rosuvastatin: most potent; 5 - 40 mg (CRESTOR®); may raise HDL a bit more & lower TG. Caution w/ Cr. Cl<30 cc/min and in Asian subpopulations at higher doses. 49 / 29

Statin Pearls • Elevated transaminases on statins; (unless reaching 3 x normal), are not a reason to stop the statin – they are a reason to watch closely. • Statin side effects are often agent specific, not always class specific. • Unexplained myalgias may occur on statins without CK elevation. Try a different statin. 50 / 29

Statin Pearls • Rhabdomyolysis is uncommon unless CK is elevated to 10 x normal. Usually occurs in patients with multiple co-morbidities. • Unless you enjoy driving yourself nuts; do not check CK serially in patients on statins. Remember vigorous yard work will bump your CK! Some think a baseline CK may be helpful. • But – what about the PROVE-IT study? (NEJM 8 April 2004) 51 / 29

PROVE-IT Trial • Designed to “PROVE” that 80 mg atorvastatin was no better than 40 mg pravastatin in secondary prevention. • But, atorvastatin was superior as early as 30 days of therapy. In just 24 mths the atorvastatin group (mean. LDL=62) had 16% less of all CV events. 28% less mortality than pravastatin group (mean. LDL=95) 52 / 29

PROVE-IT Trial • WOW! • Evidence from mammalian species had shown that atherogenesis stops & reverses at an LDL <80 – now some clinical outcome data. 53 / 29

NCEP Update 13 July 2004 • Circulation 13 July 2004: 227 -239 • Added the results of PROVE-IT, HPS, PROSPER, ALLHAT, ASCOT • Confirmed ATP-III and added that in very high risk an LDL goal <70 was optional • For patients at moderately high risk = 10 -20% Framingham risk; LDL <100 new goal • Felt that drug treatment should aim for at least a 30 -40% LDL reduction. 54 / 29

Updated ATP-III Guidelines RISK LDL HIGH >20% 10 yr Mod. High 10 -20% Moderate <10% 10 yr LOW <70 mg/dl >100 mg/dl or <100 mg Optional <100 mg/dl >130 mg/dl or 100 -130 Optional <130 mg/dl >160 mg/dl <160 mg/dl TLC >160 mg/dl DRUGS >190 mg/dl 55 / 29

TNT Study “Treat to New Targets” • NEJM 7 April 2005: Prospective trial at lowering LDL well below 100 mg/dl in adults with CHD (secondary prevention) • 10, 001 patients; 2 groups for 4. 9 years with mean LDL = 99 mg/dl before study – 10 mg atorvastatin (mean LDL=101 mg/dl) – 80 mg atorvastain (mean LDL=77 mg/dl) 56 / 29

TNT - Results • Side Effects: increased LFT’s in 0. 2% of patients on low dose and 1. 2% on high dose. No change in rhabdomyolysis risk. • Results: Relative risk reduction of 22% and absolute risk reduction of 2. 2% in major cardiovascular events for group with LDL <80 versus group with LDL=101. • More evidence to lower our LDL goals… 57 / 29

NCEP/ATP III – Step 8 • Identify Metabolic Syndrome: (3 of 5) – SBP>130, FBS>110, TG>150, HDL<40 in men and <50 in women, waist>40”men, 35”women Aggressively: – Treat underlying causes of overweight and physical inactivity. – Treat HTN, use ASA for CHD patients 58 / 29

NCEP/ATP III – Step 9 • Treat elevated TG (>150 mg/dl) – First lower LDL; if TG still >200 consider adding/increasing drug therapy – But, if TG >500 mg/dl, first lower triglycerides to prevent pancreatitis. When they are <500 then return to LDL lowering – Treat HDL <40 after lowering LDL. 59 / 29

CASES • All real cases. No “perfect answers”. • All present real Family Practice dilemmas. • Will use the evidence to help formulate a “best” answer. • Use cases to convey cutting edge info. 60 / 29

Case # 4 – “Middle-of the Road” • 45 year old woman who on a routine lipid screen has the following values: • TC = 203 HDL=48 TG = 155 LDL = 124 • PMHx: negative, smoker • Meds: daily vitamin • FHx: MI in F age 60, M age 64 • PE: 65” 130 lbs P=72 BP=118/68 61 / 29

Case #4 – “Middle of the Road” • Risk Factors: 2 ; Framingham = 5% risk • NCEP/ATP III says that she is at her LDL goal; e. g. <130 • But, concerns remain: FHx, Smoking, HDL is <50 & TG >150; both less than ideal. • What do you do with this “middle-of-theroad” risk profile? 62 / 29

Case# 4 – Middle of the Road • • Consider a new idea: measure her hs-CRP Facts: CRP is a marker of inflammation. ASCVD is a disease of inflammation Multiple prospective epidemiological (vs. interventional studies) have shown that CRP can predict MI, CVA, PAD, sudden cardiac death. 63 / 29

Case #4 – Middle of the Road • Hs-CRP assays are now widely available; can check non-fasting, anytime of day. • < 1 mg/l = low risk • 1 -3 mg/l = moderate risk • >3 mg/l = high risk • >10 mg/l = invalid for cardiac risk prediction; consider 1° inflammatory disease, trauma, serious infection. 64 / 29

Case #4 – Middle of the Road • PRINCE (PRavastatin INflammation/Crp Evaluation trial; JAMA 2001: 286; 64 -70. And other trials have proven that Statins lower CRP 15 -25% within 6 weeks of initiation. • Weight loss, exercise and smoking cessation also lower CRP. 65 / 29

Case # 4 – Middle of the Road • CARE & AFCAPS/TEXCAPS both suggest that the benefit of statin therapy among those with low LDL but high CRP may be as large as those with overt hyperlipidemia. • How to answer this ? • 2003: 15, 000 patients with LDL<130 but CRP above 2. 0 mg/l (JUPITER). All will be put on CRESTOR® for prevention. What will happen? 66 / 29

Case # 4 – Middle of the Road • What does this mean for our patient? • CRP is most useful in those judged at intermediate risk and in primary prevention. • Review; 45 yr old woman with an LDL<130 but +FHX and other borderline risks…eg a 5% Framingham risk • HOW about checking an hs-CRP to further assess her risk ? 67 / 29

Case # 4 – Middle of the Road • CRP = 3. 2 mg/l HIGH risk • Studies have proven she is in fact at risk; more than her LDL would tell us. What to do? • Smoking cessation will lower CRP • Statins will lower her CRP • But, no prospective proof that this will change her outcome. It is your call, Doctor! 68 / 29

Other Novel Risk Factors • • EBCT (coronary Ca++ score) Lp (a) lipoprotein, Apo B, LDL particle size Homocysteine Plasma Adiponectin 69 / 29

EBCT/Coronary Ca++ scores • Coronary Ca++ occurs due to ASCVD • Normal score=0 -10; 11 -100 = mild disease, 101400 = non-obstructive disease, >400 = obstructive • Significant false positives and poor data in women and younger patients • It may not provide incremental information above that obtained with conventional risk factor assessment; it is an alternative. 70 / 29

EBCT • Like with hs-CRP, it is not very useful in low risk or very high risk patients. It significantly correlates w/ cheaper hs-CRP. • Best used in intermediate risk folks where it might change treatment approach. • In patients w/ intermediate risk an EBCT score >80 has a sensitivity of 85% and a specificity of 75% for the risk of events. 71 / 29

EBCT/Coronary Ca++ Scores • USPSTF: Feb 2004; “D” recommendation for adults at low risk. “absence of evidence that detection ultimately results in improved health outcomes, and because false positive tests are likely to cause harm…” • “I” recommendation for those at high risk 72 / 29

Homocysteine • High plasma homocysteine may be directly related to atherosclerosis development. • Homocysteine may enhance inflammation & thrombosis. • There may be no causal association between elevated homocysteine and CV disease risk. • New Evidence!! 73 / 29

Homocysteine • NEJM; 13 April 2006; 2 studies re: homocysteine lowering • #1: Secondary prevention: 5522 patients: placebo vs 2, 5 mg Folate+B 6+B 12: did not reduce the risk of cardiovascular event, more pts in Tx had unstable angina. • #2: 3749 pts post-MI: “treatment with Bvitamins did not lower risk of recurrent CV disease. A harmful effect of B-vitamin Tx was suggested. ” 74 / 29

Lipid Sub-fractions & other markers • Lipoprotein a, Apolipoprotein B, LDL particle size – All have predictive value for CHD, indeed LDL particle size is more precise than LDL alone. But not widely available, expensive, less reproducible and still no outcome studies. 75 / 29

Case # 5 – The Unreachable Goal • 60 yr old male returns to see you 3 months after a 4 v. CABG. He feels great. At his last visit with his CT surgeon he was told; “follow-up with your family doctor to get your cholesterol in control” • PMHX: HTN x 20 yrs, BPH, ED, mild OA • MEDS: ASA, Metoprolol 50 mg po bid, Viagra®, Simvastatin 20 mg po qd • FHX: F with CVA at 68 76 / 29

Case # 5 – The Unreachable Goal • PE: 70” 160 lbs P=60 BP=124/76 • Cor: RRR, no m/r/g, no jvd, healed median sternotomy scar • Ext: no edema Lungs: slight dec. breath sounds • TC=180, HDL=42 TG=100 LDL=118 77 / 29

Case # 5 – The Unreachable Goal • Risk Assessment = he has CHD; 2° prev. • Goal LDL is <100 per ATP III (<70 -80 TNT trial data and ATP update) • At this level atherogenesis seems to arrest • At an LDL of 80 in mammalian species atherogenesis reverses. Also the PROVE-IT trial shows that an LDL of 62 was superior to an LDL of 95. 78 / 29

Case #5 – The Unreachable Goal • You decide to increase the simvastatin to 40 mg po qd. • 6 weeks later; TC= 170 TG=105 HDL=42 LDL=107 • What do you do? 79 / 29

Case # 5 – The Unreachable Goal • Many options: 1)increase simvastatin to 80 mg or change to atorvastatin or rosuvastatin. • PROBLEM: inc risk of side effects and less LDL lowering effect as you inc statin doses. For every doubling of dose, LDL decreases by only 6 %. A threefold higher dose by 12% and a fourfold increase lowers LDL cholesterol by only 18%. 80 / 29

Case # 5 – The Unreachable Goal • 2. ) Add Ezetimibe 10 mg po qd: less chance of side effects; should help to reach goal LDL easily. • 3. ) Intensify diet; Ornish Plan; add soluble fiber, add soy, add omega-3 fatty acids. • 4. ) Be satisfied and await more trials… 81 / 29

Summary • 8 Points to make you strong • 1) 1° & 2° prevention of ASCVD are possible! 2) NCEP/ATP III at www. nhlbi. nih. gov is useful. 3) The key step is risk assessment & then tailoring treatment to individual risk. 82 / 29

Summary – 8 Points • 3) Better medication options are a help: Ezetimibe, Advicor®, new statins and a cleaner understanding of statin side effects • 4)Attack the metabolic syndrome!! A multi -modal treatment plan is best. • 5) Don’t ignore a chance for prevention because your patient is >70 or <35. 83 / 29

Summary – 8 Points • 6) hs-CRP is a powerful new tool to predict risk; especially in those at intermediate risk. But, we need prospective proof that lowering it will help reduce ASCVD endpoints. 7) Try to get to goal; anticipate new ATP-IV guidelines. 84 / 29

Thanks for your Attention! 85 / 29